Clinical Trials
Scope & Guideline
Driving progress in medicine with impactful studies.
Introduction
Aims and Scopes
- Clinical Trial Methodologies:
The journal emphasizes the development and application of advanced statistical methods and trial designs, including adaptive designs, Bayesian approaches, and innovative monitoring techniques. - Ethical Considerations in Trials:
It explores ethical implications in clinical trials, particularly concerning informed consent, participant engagement, and the transparency of trial processes. - Real-World Evidence:
The journal encourages the integration of real-world data and observational studies to complement traditional randomized controlled trials, reflecting the complexities of clinical practice. - Patient-Centric Approaches:
There is a strong focus on patient-reported outcomes and the importance of incorporating patient perspectives into trial design and outcome assessment. - Diversity and Inclusion:
The journal addresses issues of demographic diversity in clinical trial participation, aiming to improve representation and accessibility for underrepresented groups.
Trending and Emerging
- Adaptive Trial Designs:
There is a marked increase in interest in adaptive trial designs, which allow for modifications to the trial procedures based on interim results, enhancing efficiency and ethical considerations. - Integration of Digital Health Technologies:
Recent publications highlight the growing role of digital health technologies, including telemedicine and mobile health applications, in facilitating clinical trials and improving participant engagement. - Focus on Health Equity:
Emerging themes emphasize the importance of health equity in clinical research, addressing disparities in trial participation and outcomes among different demographic groups. - Use of Real-World Evidence:
The rising incorporation of real-world evidence is becoming a focal point, reflecting a trend towards utilizing observational data to complement clinical trial findings and enhance generalizability. - Patient Engagement and Experience:
There is an increasing emphasis on understanding the patient experience and incorporating patient feedback into trial designs, demonstrating a shift towards more patient-centered research methodologies.
Declining or Waning
- Traditional Trial Designs:
There seems to be a waning interest in conventional trial designs, such as simple parallel-group randomized trials, as researchers increasingly favor more complex, adaptive, and pragmatic approaches. - Single-Endpoint Studies:
Research focusing solely on a single primary endpoint is declining, with a shift towards composite endpoints and multi-faceted outcome measures that provide a more comprehensive assessment of treatment effects. - Limited Statistical Methods:
The use of basic statistical approaches is decreasing, as the field moves towards more sophisticated modeling and analysis techniques that can better handle the complexities of clinical trial data. - Focus on Drug Development:
There is a noted decrease in studies exclusively centered on traditional pharmacological trials, as the journal broadens its scope to include behavioral, non-pharmacological, and holistic health interventions.
Similar Journals
CLINICAL PHARMACOLOGY & THERAPEUTICS
Advancing pharmacological knowledge for better patient care.CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.
International Journal of Biostatistics
Empowering Evidence-Based Medicine.The International Journal of Biostatistics, published by Walter de Gruyter GmbH, stands as a critical platform for advancements in the fields of biostatistics and applied statistics in medicine. With an ISSN of 2194-573X and an E-ISSN of 1557-4679, this journal has gained recognition for its rigorous peer-reviewed articles that bridge theoretical statistics and its practical applications in health sciences, maintaining a commendable Q2 quartile ranking in both Medicine and Statistics categories as of 2023. Hosted in Germany, the journal's pivotal role lies in disseminating innovative research findings that guide public health decisions and inform healthcare policy, thus appealing to a diverse readership including researchers, healthcare professionals, and students. Although the journal operates under a subscription model, it remains committed to providing valuable insights into the statistical methods that support evidence-based medicine and improve health outcomes globally. For those engaged in the evolving landscape of biostatistics, the International Journal of Biostatistics serves as an indispensable resource through its comprehensive coverage from 2005 to 2024.
Journal of Biopharmaceutical Statistics
Advancing drug development through statistical excellence.Journal of Biopharmaceutical Statistics, published by Taylor & Francis Inc, is a premier scholarly journal that has been contributing to the fields of biostatistics and pharmacology since its inception in 1991. With an impressive track record spanning over three decades, it holds a significant place in the academic landscape, particularly evidenced by its Q2 quartile rankings in Pharmacology, Pharmacology (Medical), and Statistics and Probability as of 2023. The journal serves as a vital platform for researchers, professionals, and students, disseminating critical statistical methodologies and innovative analyses that enhance drug development and biopharmaceutical research. Although not open access, it provides invaluable insights through meticulously peer-reviewed articles that tackle pressing issues in pharmacometric modeling, clinical trial design, and statistical theory. As the biopharmaceutical industry evolves, Journal of Biopharmaceutical Statistics remains pivotal in fostering scientific discovery and excellence.
Neurology and Clinical Neuroscience
Illuminating the complexities of the nervous system.Neurology and Clinical Neuroscience, published by WILEY, is a pivotal peer-reviewed journal dedicated to advancing knowledge in the fields of neurology and clinical neuroscience. With an ISSN of 2049-4173, it encompasses a diverse range of topics related to neurological disorders, offering a platform for groundbreaking research and clinical practices. Although the journal does not currently operate under an open access model, it aims to foster an inclusive academic environment by providing high-quality content that is accessible to both specialists and general practitioners in the medical community. Despite its relatively recent establishment from 2013 to 2024, the journal has gained recognition with Scopus rankings highlighting its role in clinical neurology and neuroscience spheres. It serves as an essential resource for researchers, professionals, and students seeking to expand their understanding and engage in current discussions surrounding neurological health and diseases.
CPT-Pharmacometrics & Systems Pharmacology
Fostering collaboration in the realms of pharmacology and modeling.CPT-Pharmacometrics & Systems Pharmacology, published by WILEY, is a leading open access journal dedicated to advancing the fields of pharmacometrics and systems pharmacology. Since its inception in 2012, it has established itself as a vital resource for researchers and practitioners, boasting a remarkable impact factor and occupying prestigious Q1 quartiles in categories such as Cardiology and Cardiovascular Medicine, Modeling and Simulation, and Pharmacology (Medical). The journal covers a broad spectrum of topics aimed at enhancing the understanding of drug development, efficacy, and patient safety through innovative modeling and simulation approaches. With its consistent ranking in the top tiers of its field, CPT-Pharmacometrics & Systems Pharmacology provides invaluable insights and fosters scholarly dialogue among its audience, including researchers, educators, and students. The journal is accessible to all, promoting knowledge dissemination and collaborative growth in the pharmacology community.
Reviews on Recent Clinical Trials
Enhancing Knowledge Through Comprehensive Reviews.Reviews on Recent Clinical Trials, published by Bentham Science Publishers Ltd, is a distinguished journal in the medical and pharmacological fields, assessing the latest advancements in clinical research since its inception in 2006. With a focus on integrating multidisciplinary approaches to evaluating clinical trial methodologies, the journal caters to a diverse audience of researchers, professionals, and students keen on enhancing their knowledge and understanding of innovative therapeutic strategies and drug developments. Notably positioned in the Q3 quartile as ranked by Scopus for both 'Medicine (miscellaneous)' and 'Pharmacology', the journal illustrates a growing academic influence, evidenced by its Scopus rankings—holding a commendable 72nd percentile in general medicine and a 33rd percentile in pharmacology. While the journal is not open access, it remains committed to disseminating high-quality, peer-reviewed content that drives forward the conversation in clinical research. For those interested in staying abreast of novel findings and comprehensive reviews within the clinical trial landscape, Reviews on Recent Clinical Trials stands out as an essential resource.
Contemporary Clinical Trials
Driving Change Through Open Access ResearchContemporary Clinical Trials, published by Elsevier Science Inc, stands at the forefront of clinical research, providing a dedicated platform for the dissemination of innovative studies and methodologies in medicine and pharmacology. With an impressive impact factor reflecting its consistent contributions to the field, this journal is categorized in the Q1 quartile for both Medicine (miscellaneous) and Pharmacology (medical) as of 2023. The journal's scope encompasses a broad range of topics pertinent to clinical trial design, execution, and analysis, aiming to enhance the effectiveness and safety of therapeutic interventions. Operating under an Open Access model, it ensures that the latest research is accessible to a global audience, fostering collaboration and discussion among researchers, professionals, and students alike. In publishing high-quality articles since its inception in 2005, Contemporary Clinical Trials continues to shape the future of clinical research with its commitment to excellence and innovation.
EXPERT OPINION ON EMERGING DRUGS
Bridging research and practice in emerging therapeutics.EXPERT OPINION ON EMERGING DRUGS, published by Taylor & Francis Ltd, stands at the forefront of the pharmacological sciences, focusing on the rapid development and evaluation of innovative therapeutic agents. With an impressive impact factor that reflects its contributions to the field, this journal is indexed under ISSN 1472-8214 and E-ISSN 1744-7623. The journal has consistently attained high recognition, currently holding a Q2 ranking in Pharmacology and a Q1 ranking in Pharmacology (medical) as of 2023, which places it within the top tiers of scholarly publications. Covering a broad range of topics related to emerging pharmaceuticals, it aims to bridge the gap between research and clinical practice by providing critical reviews, expert opinions, and insightful analyses. Based in the United Kingdom and actively published since 2000, the journal seeks to inform and inspire researchers, professionals, and students alike, offering a platform to foster collaboration and insight within the ever-evolving domain of drug development and pharmacotherapy.
Translational and Clinical Pharmacology
Elevating Standards in Translational ResearchTranslational and Clinical Pharmacology, published by KSCPT, is an esteemed journal that serves as a vital source of knowledge in the field of pharmacology, particularly focusing on the translational aspects that bridge laboratory research and clinical applications. Established in 2014, this journal aims to disseminate high-quality research and reviews pertaining to drug development, therapeutics, and the underlying mechanisms of action in the medical realm. With an ISSN of 2289-0882 and an E-ISSN of 2383-5427, it holds a significant position with a Q3 ranking in the pharmacology category as of 2023, emphasizing its role in advancing scientific understanding within this crucial discipline. While it operates as a traditional subscription-based journal, its output remains accessible through various academic platforms, contributing to the global discourse in pharmacology. Researchers, professionals, and students will find value in its insightful articles and comprehensive studies, underscoring the journal’s commitment to enhancing pharmacological knowledge and practice.
JTO Clinical and Research Reports
Pioneering Excellence in Clinical and Research InsightsJTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.